{
  "id": 5914,
  "text": "Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial ( Gynecologic Oncology Group 240)[J].Lancet, 2017, 390(10103): 1654-1663.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial ( Gynecologic Oncology Group 240)[J].Lancet, 2017, 390(10103): 1654-1663.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "贝伐单抗是一种用于治疗晚期宫颈癌的药物。根据一项随机、对照、开放标签的三期临床试验研究，贝伐单抗的使用与晚期宫颈癌患者的总体生存率的改善有关。该研究表明，在接受贝伐单抗治疗的患者中，总体生存率显著高于未接受该治疗的患者。此外，贝伐单抗治疗的患者可能会经历不同类型的不良事件，但总体来说，其使用在延长生存期方面显示了积极的效果和显著的获益。需要注意的是，在使用贝伐单抗时，最好在专业医疗人员的指导下进行，以提高疗效并尽量减少不良事件的发生。",
  "query": "在治疗晚期宫颈癌时，贝伐单抗的使用如何影响患者的总体生存率及其不良事件的发生率？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在治疗晚期宫颈癌时，贝伐单抗的使用如何影响患者的总体生存率及其不良事件的发生率？\n\n<reference text>: Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial ( Gynecologic Oncology Group 240)[J].Lancet, 2017, 390(10103): 1654-1663.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "贝伐单抗是一种用于治疗晚期宫颈癌的药物。根据一项随机、对照、开放标签的三期临床试验研究，贝伐单抗的使用与晚期宫颈癌患者的总体生存率的改善有关。该研究表明，在接受贝伐单抗治疗的患者中，总体生存率显著高于未接受该治疗的患者。此外，贝伐单抗治疗的患者可能会经历不同类型的不良事件，但总体来说，其使用在延长生存期方面显示了积极的效果和显著的获益。需要注意的是，在使用贝伐单抗时，最好在专业医疗人员的指导下进行，以提高疗效并尽量减少不良事件的发生。"
}